Effect of Hericium Erinaceus on Clinical Patients With Hearing Impairment

Tinnitus Clinical Trial

Official title:

Effect of Hericium Erinaceus on Clinical Patients With Hearing Impairment and Possible Mechanisms

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT03632512
• Other study ID #: B10604025
• Status: Recruiting
• Phase: N/A
• Start date: May 18, 2018
• Est. completion date: June 30, 2020

Study information

• Verified date: August 2018
• Source: Providence University, Taiwan
• Contact: Yin-Ching Chan, PhD
• Phone: 886921376777
• Email: ycchan[@]pu.edu.tw
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This study aims to investigate the effect of Hericium Erinaceus on clinical patients with hearing impairment and possible mechanisms. Subjects with hearing impairment will be enrolled and randomly divided into experimental or control group supplemented with Hericium Erinaceus (430 mg/kg/day) or placebo, respectively for eight months. Basic characteristics will be evaluated at baseline by questionnaire. The hearing, liver and kidney functions, and neurotrophic factors will be examined at baseline, 4th month and 8th month.

Description:

This study aims to investigate the effect of Hericium Erinaceus on clinical patients with hearing impairment and possible mechanisms. Subjects with hearing impairment will be enrolled. Inclusion criteria were 50 to 79 years old with symmetric sensorineural hearing loss, subjective sensorineural tinnitus, and all frequencies differed of ears less than 15 dB. Exclusion conditions were patients with abnormal liver and kidney function, normal hearing, severe and very severe hearing loss, no tinnitus or non-subjective sensorineural tinnitus, moderate or more cognitive impairment, patients unable to understand the details of this study or patients unable to co-examine, history of alcohol or drug abuse, history of high ambient noise exposure, bone tone air gap of pure tone hearing threshold greater than 10 dB, and audiogram 4 kHz air conduction threshold greater than 8 kHz, 20 dB airway threshold, hearing impairment before age 30, and inability to understand the details of this study. Participants will randomly divide into experimental or control group supplemented with Hericium Erinaceus (430 mg/kg/day) or placebo, respectively for eight months by a prospective, randomized, double-blind approach. Basic characteristics will be evaluated at baseline by questionnaire. The status of hearing, and CBC, GOT, GPT, BUN, Creatinine, NGF and BDNF expressions in blood will be examined at baseline, 4th month and 8th month.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 80
• Est. completion date: June 30, 2020
• Est. primary completion date: January 17, 2019
• Accepts healthy volunteers: No
• Gender: All
• Age group: 50 Years to 79 Years

Eligibility

Inclusion Criteria:

• Patients aged 50 to 79 years old with symmetric sensorineural hearing loss, subjective sensorineural tinnitus, and all frequencies differed of ears less than 15 dB.

Exclusion Criteria:

• Patients with abnormal liver and kidney function, normal hearing, severe and very severe hearing loss, no tinnitus or non-subjective sensorineural tinnitus, moderate or more cognitive impairment , patients unable to understand the details of this study or patients unable to co-examine, history of alcohol or drug abuse, history of high ambient noise exposure, bone tone air gap of pure tone hearing threshold greater than 10 dB, and audiogram 4 kHz air conduction threshold greater than 8 kHz, 20 dB airway threshold, hearing impairment before age 30, and inability to understand the details of this study.

Related Conditions & MeSH terms

• Deafness
• Hearing Loss
• Tinnitus

Intervention

Dietary Supplement:
• Hericium honey bolus
The subjects of the experimental group will be supplemented with Hericium Erinaceus honey bolus(430 mg/kg/day) for eight months.
• Placebo honey bolus
The subjects of the control group will be supplemented with Placebo honey bolus(8 bolus/ day) for 8 months.

Locations

Country	Name	City	State
Taiwan	Departments of Otolaryngology and Neurosurgery of Dalin Tzu Chi Hospital	Dalin	Chiayi

Sponsors (1)

Lead Sponsor	Collaborator
Providence University, Taiwan

Country where clinical trial is conducted

Taiwan, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	1.Change of Tinnitus status evaluates by Tinnitus handicap inventory (THI)	The status of tinnitus will be evaluated by Tinnitus handicap inventory (THI). THI is divided into three categories, including the functional (12 questions), emotional (8 questions), and catastrophic (5 questions) subscore. A total of 25 questions are used. The answer will be divided into three levels (will, sometimes, will not), and be scored into 4, 2 and 0 point, respectively. The subscore of functional (12 questions), emotional (8 questions), and catastrophic (5 questions) are 48, 32, and 20, respectively. The highest total score is 100 points. The higher the score, the more the tinnitus is. The difference of score will be compared from the baseline with 4th and 8th month.	Baseline, 4th month and 8th month
Primary	Change of Tinnitus severity evaluates by visual analog scale (VAS)	The severity of tinnitus will be scored with a visual analog scale (VAS) from point 0 to point 10 by subject. The difference of score will be compared from the baseline with 4th and 8th month.	Baseline, 4th month and 8th month
Primary	Changes of hearing obstacle average measure by Pure Tone Audiometry(PTA)	Pure tone threshold of subjects will be measured by Pure Tone Audiometry (PTA) to evaluate the changes from baseline ageing hearing obstacle average (dB HL) with 4th and 8th month.	Baseline, 4th month and 8th month
Primary	Changes of speech recognizing measure by Speech Audiometry.	The Speech Audiometry is used to evaluate the changes of baseline speech recognizing (dB HL) and speech speech recognition rate(%) with 4th and 8th month.	Baseline, 4th month and 8th month
Primary	Changes of NGF and BDNF levels of blood investigate by enzyme-linked immunosorbent assay (ELISA)	The NGF and BDNF levels of blood will be analyzed by enzyme-linked immunosorbent assay (ELISA) to detect the presence of NGF and BDNF. The NGF and BDN levels will be quantitative by the optical density (OD) of the sample comparing to a standard curve, which is a serial dilution of a known-concentration solution of the target molecule. The difference of NGF and BDNF levels will be compared from the baseline with 4th and 8th month.	Baseline, 4th month and 8th month